Share Price and Basic Stock Data
Last Updated: January 8, 2026, 7:07 am
| PEG Ratio | -31.99 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Healthcare Global Enterprises Ltd (HCG) operates in the Hospitals & Medical Services sector, with a current share price of ₹658 and a market capitalization of ₹9,290 Cr. The company reported a total revenue of ₹1,691 Cr for the fiscal year ending March 2023, which rose to ₹1,908 Cr for March 2024, demonstrating a year-on-year growth of 12.86%. The trailing twelve months (TTM) revenue stood at ₹2,404 Cr, indicating a robust upward trajectory. Quarterly revenue figures also reflect this growth, with sales increasing from ₹420 Cr in September 2022 to ₹487 Cr in September 2023. This growth pattern, despite minor fluctuations in quarter-on-quarter performance, showcases HCG’s ability to expand its customer base and service offerings in a competitive industry. The company’s resilience is evidenced by its ongoing revenue enhancement strategies amid evolving healthcare demands.
Profitability and Efficiency Metrics
HCG reported a net profit of ₹41 Cr for the fiscal year ending March 2023, which further improved to ₹49 Cr in March 2025. The company’s operating profit margin (OPM) for FY 2025 stood at 17%, consistent with the previous year, indicating stable operational efficiency. However, the price-to-earnings (P/E) ratio is notably high at 263, suggesting that the stock is valued at a premium compared to earnings. Return on equity (ROE) was recorded at 5.14% and return on capital employed (ROCE) at 8.56%, both of which are below industry averages, indicating room for improvement in capital utilization. Additionally, the cash conversion cycle (CCC) was reported at -111 days, highlighting the company’s effective management of receivables and payables, which is a positive indicator of liquidity and operational efficiency in the healthcare sector.
Balance Sheet Strength and Financial Ratios
The balance sheet of HCG reveals total borrowings of ₹1,768 Cr against reserves of ₹780 Cr, which reflects a debt-to-equity ratio of 1.09, indicating a reliance on leverage to finance growth. While the interest coverage ratio (ICR) stands at 2.73, suggesting that HCG can comfortably cover its interest obligations, the current ratio of 0.80 indicates potential liquidity concerns. The book value per share increased to ₹66.16 by March 2025, compared to ₹59.28 in March 2024, indicating a strengthening of shareholder equity. However, the company’s high price-to-book value (P/BV) ratio of 8.13x raises questions about valuation sustainability. As HCG continues to expand, maintaining a balanced approach to debt management while improving liquidity will be crucial for long-term financial health.
Shareholding Pattern and Investor Confidence
As of September 2025, the shareholding pattern of HCG shows promoters holding 63.78%, foreign institutional investors (FIIs) at 3.59%, domestic institutional investors (DIIs) at 18.36%, and the public at 14.28%. The steady decline in promoter holding from 71.39% in December 2022 to the current level raises concerns about insider confidence, though it remains significantly high. On the other hand, the increase in DII holding from 4.41% in December 2022 to 18.36% reflects growing institutional interest and confidence in HCG’s growth prospects. The number of shareholders has also risen to 46,970, indicating an expanding retail investor base. This diversified ownership structure can enhance market stability, but the declining promoter stake may affect perceptions of governance and long-term strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, HCG’s growth trajectory appears promising, bolstered by increasing healthcare demand and strategic expansion initiatives. However, the company faces risks primarily associated with high leverage, as evidenced by its debt levels, which could affect financial flexibility and increase vulnerability to interest rate fluctuations. Additionally, the high P/E and P/BV ratios suggest that the stock may be overvalued, potentially leading to volatility if growth expectations are not met. HCG must focus on improving profitability metrics, particularly ROE and ROCE, to instill investor confidence. If the company successfully enhances its operational efficiency while managing debt levels, it could position itself favorably for sustainable growth. Conversely, failure to address these risks could lead to a reevaluation of its market positioning and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 51.9 Cr. | 155 | 187/120 | 10.6 | 117 | 2.26 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.60 Cr. | 9.29 | 20.8/7.08 | 107 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.8 | 98.7/55.2 | 24.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.0 Cr. | 3.70 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,729.71 Cr | 713.45 | 92.58 | 93.18 | 0.32% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 425 | 442 | 461 | 487 | 470 | 495 | 526 | 554 | 559 | 585 | 613 | 647 |
| Expenses | 345 | 349 | 365 | 386 | 402 | 391 | 403 | 435 | 451 | 470 | 480 | 505 | 524 |
| Operating Profit | 75 | 76 | 76 | 74 | 85 | 79 | 92 | 91 | 102 | 88 | 106 | 108 | 123 |
| OPM % | 18% | 18% | 17% | 16% | 17% | 17% | 19% | 17% | 18% | 16% | 18% | 18% | 19% |
| Other Income | 2 | 4 | 5 | 3 | 3 | 6 | 9 | 9 | 11 | 6 | 10 | 8 | 3 |
| Interest | 26 | 27 | 26 | 26 | 27 | 29 | 27 | 34 | 36 | 41 | 44 | 45 | 44 |
| Depreciation | 41 | 41 | 42 | 41 | 43 | 44 | 46 | 47 | 50 | 57 | 58 | 58 | 63 |
| Profit before tax | 10 | 11 | 13 | 11 | 18 | 11 | 28 | 19 | 28 | -3 | 14 | 12 | 20 |
| Tax % | 47% | 63% | 57% | 65% | 40% | 69% | 17% | 28% | 25% | -335% | 50% | 50% | -4% |
| Net Profit | 5 | 4 | 6 | 4 | 11 | 3 | 23 | 14 | 21 | 8 | 7 | 6 | 21 |
| EPS in Rs | 0.53 | 0.54 | 0.60 | 0.55 | 0.97 | 0.41 | 1.53 | 0.87 | 1.29 | 0.50 | 0.53 | 0.34 | 1.15 |
Last Updated: January 1, 2026, 12:16 pm
Below is a detailed analysis of the quarterly data for Healthcare Global Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 647.00 Cr.. The value appears strong and on an upward trend. It has increased from 613.00 Cr. (Jun 2025) to 647.00 Cr., marking an increase of 34.00 Cr..
- For Expenses, as of Sep 2025, the value is 524.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 505.00 Cr. (Jun 2025) to 524.00 Cr., marking an increase of 19.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 123.00 Cr.. The value appears strong and on an upward trend. It has increased from 108.00 Cr. (Jun 2025) to 123.00 Cr., marking an increase of 15.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 19.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Sep 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 45.00 Cr. (Jun 2025) to 44.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 63.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.00 Cr. (Jun 2025) to 63.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is -4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 50.00% (Jun 2025) to -4.00%, marking a decrease of 54.00%.
- For Net Profit, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 15.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.15. The value appears strong and on an upward trend. It has increased from 0.34 (Jun 2025) to 1.15, marking an increase of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 519 | 584 | 700 | 829 | 976 | 1,092 | 1,009 | 1,395 | 1,691 | 1,908 | 2,218 | 2,404 |
| Expenses | 413 | 443 | 499 | 595 | 713 | 864 | 936 | 887 | 1,161 | 1,394 | 1,581 | 1,835 | 1,979 |
| Operating Profit | 38 | 76 | 85 | 105 | 116 | 112 | 157 | 122 | 234 | 297 | 327 | 384 | 425 |
| OPM % | 9% | 15% | 15% | 15% | 14% | 11% | 14% | 12% | 17% | 18% | 17% | 17% | 18% |
| Other Income | 3 | 0 | -2 | 10 | 25 | 10 | 10 | -72 | 110 | 15 | 24 | 39 | 26 |
| Interest | 32 | 34 | 38 | 23 | 42 | 70 | 138 | 119 | 98 | 104 | 109 | 155 | 174 |
| Depreciation | 36 | 39 | 44 | 57 | 71 | 85 | 148 | 159 | 158 | 163 | 174 | 211 | 235 |
| Profit before tax | -27 | 3 | 0 | 35 | 27 | -33 | -119 | -229 | 88 | 45 | 68 | 57 | 42 |
| Tax % | 20% | -56% | -730% | 34% | 38% | -7% | 5% | -3% | 56% | 61% | 39% | 14% | |
| Net Profit | -32 | 5 | 2 | 23 | 17 | -31 | -125 | -221 | 39 | 18 | 41 | 49 | 41 |
| EPS in Rs | -5.21 | 0.12 | -0.17 | 2.59 | 2.36 | -2.82 | -12.03 | -15.43 | 3.87 | 2.11 | 3.46 | 3.19 | 2.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 115.62% | -60.00% | 1050.00% | -26.09% | -282.35% | -303.23% | -76.80% | 117.65% | -53.85% | 127.78% | 19.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | -175.62% | 1110.00% | -1076.09% | -256.27% | -20.87% | 226.43% | 194.45% | -171.49% | 181.62% | -108.27% |
Healthcare Global Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 19% |
| 3 Years: | 73% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 37% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 5:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 | 141 |
| Reserves | 196 | 210 | 341 | 347 | 428 | 389 | 293 | 572 | 731 | 721 | 686 | 783 | 780 |
| Borrowings | 292 | 349 | 324 | 420 | 464 | 658 | 1,347 | 977 | 915 | 901 | 1,274 | 1,837 | 1,768 |
| Other Liabilities | 133 | 147 | 294 | 372 | 461 | 515 | 518 | 357 | 433 | 549 | 601 | 780 | 897 |
| Total Liabilities | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
| Fixed Assets | 512 | 528 | 583 | 685 | 828 | 970 | 1,646 | 1,382 | 1,547 | 1,553 | 1,758 | 2,442 | 2,430 |
| CWIP | 11 | 42 | 121 | 148 | 174 | 153 | 46 | 30 | 22 | 18 | 83 | 25 | 96 |
| Investments | 2 | 0 | 64 | 11 | 53 | 49 | 34 | 26 | 9 | 10 | 10 | 11 | 13 |
| Other Assets | 164 | 205 | 275 | 381 | 385 | 478 | 520 | 593 | 641 | 730 | 850 | 1,062 | 1,048 |
| Total Assets | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
Below is a detailed analysis of the balance sheet data for Healthcare Global Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2025) to 141.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 780.00 Cr.. The value appears to be declining and may need further review. It has decreased from 783.00 Cr. (Mar 2025) to 780.00 Cr., marking a decrease of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,768.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 1,837.00 Cr. (Mar 2025) to 1,768.00 Cr., marking a decrease of 69.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 897.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 780.00 Cr. (Mar 2025) to 897.00 Cr., marking an increase of 117.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,586.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,430.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,442.00 Cr. (Mar 2025) to 2,430.00 Cr., marking a decrease of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 71.00 Cr..
- For Investments, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,048.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,062.00 Cr. (Mar 2025) to 1,048.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,586.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
However, the Borrowings (1,768.00 Cr.) are higher than the Reserves (780.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -254.00 | -273.00 | -239.00 | -315.00 | -348.00 | -546.00 | 156.00 | -855.00 | -681.00 | -604.00 | 326.00 | 383.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 | 66 |
| Inventory Days | 33 | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 | 33 |
| Days Payable | 193 | 208 | 264 | 272 | 274 | 303 | 234 | 221 | 199 | 214 | 216 | 210 |
| Cash Conversion Cycle | -117 | -127 | -188 | -178 | -171 | -200 | -136 | -121 | -112 | -116 | -127 | -111 |
| Working Capital Days | -20 | -65 | -96 | -112 | -74 | -110 | -102 | -26 | -43 | -40 | -70 | -91 |
| ROCE % | 1% | 7% | 6% | 7% | 6% | 3% | 1% | -1% | 5% | 8% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 4,400,000 | 0.47 | 321.35 | N/A | N/A | N/A |
| Nippon India ELSS Tax Saver Fund | 3,500,000 | 1.65 | 255.62 | N/A | N/A | N/A |
| Axis Small Cap Fund | 1,690,271 | 0.46 | 123.45 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 1,017,366 | 0.56 | 74.3 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 939,574 | 5.13 | 68.62 | 880,171 | 2025-12-15 01:12:28 | 6.75% |
| Tata Focused Fund | 758,709 | 2.95 | 55.41 | N/A | N/A | N/A |
| Motilal Oswal Balance Advantage Fund | 750,000 | 5.85 | 54.78 | N/A | N/A | N/A |
| Bandhan Large & Mid Cap Fund | 419,885 | 0.24 | 30.67 | N/A | N/A | N/A |
| Bandhan Midcap Fund | 203,141 | 0.75 | 14.84 | N/A | N/A | N/A |
| Axis Value Fund | 78,545 | 0.48 | 5.74 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.19 | 3.46 | 2.11 | 4.14 | -17.02 |
| Diluted EPS (Rs.) | 3.14 | 3.43 | 2.10 | 3.97 | -17.02 |
| Cash EPS (Rs.) | 18.61 | 15.46 | 13.02 | 14.29 | -4.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Revenue From Operations / Share (Rs.) | 159.44 | 136.97 | 121.58 | 100.55 | 80.84 |
| PBDIT / Share (Rs.) | 30.28 | 24.88 | 22.42 | 18.03 | 11.45 |
| PBIT / Share (Rs.) | 15.12 | 12.36 | 10.67 | 6.64 | -1.25 |
| PBT / Share (Rs.) | 4.03 | 4.83 | 3.23 | 6.42 | -18.21 |
| Net Profit / Share (Rs.) | 3.45 | 2.94 | 1.27 | 2.90 | -17.61 |
| NP After MI And SOA / Share (Rs.) | 3.19 | 3.46 | 2.11 | 3.87 | -15.43 |
| PBDIT Margin (%) | 18.98 | 18.16 | 18.43 | 17.93 | 14.16 |
| PBIT Margin (%) | 9.48 | 9.02 | 8.77 | 6.60 | -1.54 |
| PBT Margin (%) | 2.52 | 3.52 | 2.65 | 6.38 | -22.52 |
| Net Profit Margin (%) | 2.16 | 2.14 | 1.04 | 2.88 | -21.78 |
| NP After MI And SOA Margin (%) | 1.99 | 2.52 | 1.73 | 3.84 | -19.08 |
| Return on Networth / Equity (%) | 4.81 | 5.83 | 3.41 | 6.17 | -27.74 |
| Return on Capital Employeed (%) | 8.44 | 8.76 | 8.50 | 5.27 | -0.99 |
| Return On Assets (%) | 1.25 | 1.77 | 1.26 | 2.42 | -9.50 |
| Long Term Debt / Equity (X) | 0.65 | 0.58 | 0.42 | 0.41 | 0.49 |
| Total Debt / Equity (X) | 1.09 | 0.81 | 0.46 | 0.46 | 0.59 |
| Asset Turnover Ratio (%) | 0.71 | 0.75 | 0.74 | 0.46 | 0.31 |
| Current Ratio (X) | 0.80 | 0.91 | 1.02 | 1.07 | 0.93 |
| Quick Ratio (X) | 0.75 | 0.85 | 0.95 | 1.01 | 0.88 |
| Inventory Turnover Ratio (X) | 46.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.73 | 3.19 | 3.01 | 2.56 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | 1.34 | 1.17 | 0.44 | -0.06 |
| Enterprise Value (Cr.) | 8223.42 | 5119.81 | 3866.17 | 3975.48 | 2784.14 |
| EV / Net Operating Revenue (X) | 3.70 | 2.68 | 2.29 | 2.84 | 2.75 |
| EV / EBITDA (X) | 19.48 | 14.77 | 12.40 | 15.86 | 19.40 |
| MarketCap / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| Price / BV (X) | 8.13 | 5.70 | 4.25 | 4.31 | 3.44 |
| Price / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.08 |
After reviewing the key financial ratios for Healthcare Global Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.19. This value is below the healthy minimum of 5. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 5. It has decreased from 3.43 (Mar 24) to 3.14, marking a decrease of 0.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.61. This value is within the healthy range. It has increased from 15.46 (Mar 24) to 18.61, marking an increase of 3.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 159.44. It has increased from 136.97 (Mar 24) to 159.44, marking an increase of 22.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 30.28. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 30.28, marking an increase of 5.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 12.36 (Mar 24) to 15.12, marking an increase of 2.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.03. This value is within the healthy range. It has decreased from 4.83 (Mar 24) to 4.03, marking a decrease of 0.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.45. This value is within the healthy range. It has increased from 2.94 (Mar 24) to 3.45, marking an increase of 0.51.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.19. This value is within the healthy range. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 18.16 (Mar 24) to 18.98, marking an increase of 0.82.
- For PBIT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.02 (Mar 24) to 9.48, marking an increase of 0.46.
- For PBT Margin (%), as of Mar 25, the value is 2.52. This value is below the healthy minimum of 10. It has decreased from 3.52 (Mar 24) to 2.52, marking a decrease of 1.00.
- For Net Profit Margin (%), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 5. It has increased from 2.14 (Mar 24) to 2.16, marking an increase of 0.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 8. It has decreased from 2.52 (Mar 24) to 1.99, marking a decrease of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has decreased from 5.83 (Mar 24) to 4.81, marking a decrease of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.44. This value is below the healthy minimum of 10. It has decreased from 8.76 (Mar 24) to 8.44, marking a decrease of 0.32.
- For Return On Assets (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.25, marking a decrease of 0.52.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.65. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 0.65, marking an increase of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.81 (Mar 24) to 1.09, marking an increase of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.75 (Mar 24) to 0.71, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.91 (Mar 24) to 0.80, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 46.46. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 46.46, marking an increase of 46.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 2.73, marking a decrease of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 24) to 1.31, marking a decrease of 0.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,223.42. It has increased from 5,119.81 (Mar 24) to 8,223.42, marking an increase of 3,103.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.70. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 3.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 19.48. This value exceeds the healthy maximum of 15. It has increased from 14.77 (Mar 24) to 19.48, marking an increase of 4.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For Price / BV (X), as of Mar 25, the value is 8.13. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 8.13, marking an increase of 2.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Healthcare Global Enterprises Ltd:
- Net Profit Margin: 2.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.44% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 263 (Industry average Stock P/E: 92.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | HCG Tower, Bengaluru Karnataka 560027 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. B S Ajai Kumar | Executive Chairman |
| Dr. Manish Mattoo | Executive Director & CEO |
| Ms. Anjali Ajaikumar | Non Exe.Non Ind.Director |
| Mr. Akshay Tanna | Non Exe.Non Ind.Director |
| Ms. Simrun Mehta | Non Exe.Non Ind.Director |
| Ms. Geeta Mathur | Ind. Non-Executive Director |
| Mr. Pradip Kanakia | Ind. Non-Executive Director |
| Mr. Rajiv Maliwal | Ind. Non-Executive Director |
| Mr. Raj Raghavan | Ind. Non-Executive Director |
| Mr. Bijou Kurien | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd's intrinsic value (as of 08 January 2026) is ₹720.31 which is 9.47% higher the current market price of ₹658.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,284 Cr. market cap, FY2025-2026 high/low of ₹805/467, reserves of ₹780 Cr, and liabilities of ₹3,586 Cr.
What is the Market Cap of Healthcare Global Enterprises Ltd?
The Market Cap of Healthcare Global Enterprises Ltd is 9,284 Cr..
What is the current Stock Price of Healthcare Global Enterprises Ltd as on 08 January 2026?
The current stock price of Healthcare Global Enterprises Ltd as on 08 January 2026 is ₹658.
What is the High / Low of Healthcare Global Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Healthcare Global Enterprises Ltd stocks is ₹805/467.
What is the Stock P/E of Healthcare Global Enterprises Ltd?
The Stock P/E of Healthcare Global Enterprises Ltd is 263.
What is the Book Value of Healthcare Global Enterprises Ltd?
The Book Value of Healthcare Global Enterprises Ltd is 65.3.
What is the Dividend Yield of Healthcare Global Enterprises Ltd?
The Dividend Yield of Healthcare Global Enterprises Ltd is 0.00 %.
What is the ROCE of Healthcare Global Enterprises Ltd?
The ROCE of Healthcare Global Enterprises Ltd is 8.56 %.
What is the ROE of Healthcare Global Enterprises Ltd?
The ROE of Healthcare Global Enterprises Ltd is 5.14 %.
What is the Face Value of Healthcare Global Enterprises Ltd?
The Face Value of Healthcare Global Enterprises Ltd is 10.0.